Press coverage about Genocea Biosciences (NASDAQ:GNCA) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Genocea Biosciences earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.103938347101 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several equities analysts have commented on the stock. Zacks Investment Research lowered shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. ValuEngine upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Piper Jaffray Companies reiterated an “overweight” rating and set a $18.00 price objective (up previously from $17.00) on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Cowen and Company reiterated an “outperform” rating and set a $40.00 price objective on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Finally, Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $16.52.
Shares of Genocea Biosciences (NASDAQ:GNCA) opened at 5.24 on Wednesday. Genocea Biosciences has a 12-month low of $3.28 and a 12-month high of $7.29. The stock has a 50 day moving average of $4.88 and a 200 day moving average of $5.53. The company’s market cap is $149.99 million.
Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). Equities research analysts predict that Genocea Biosciences will post ($1.98) earnings per share for the current fiscal year.
In other Genocea Biosciences news, CFO Jonathan Poole sold 45,000 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $6.00, for a total value of $270,000.00. Following the transaction, the chief financial officer now directly owns 84,247 shares of the company’s stock, valued at approximately $505,482. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 6.70% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.